|
1
|
Cho J, Johnson DE and Grandis JR:
Therapeutic implications of the genetic landscape of head and neck
cancer. Semin Radiat Oncol. 28:2–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wendt MK, Allington TM and Schiemann WP:
Mechanisms of the epithelial-mesenchymal transition by TGF-beta.
Futur Oncol. 5:1145–1168. 2009. View Article : Google Scholar
|
|
4
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miettinen PJ, Ebner R, Lopez AR and
Derynck R: TGF-beta induced transdifferentiation of mammary
epithelial cells to mesenchymal cells: Involvement of type I
receptors. J Cell Biol. 127:2021–2036. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smith A, Teknos TN and Pan Q: Epithelial
to mesenchymal transition in head and neck squamous cell carcinoma.
Oral Oncol. 49:287–292. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Caudroy S, Polette M, Tournier JM, Burlet
H, Toole B, Zucker S and Birembaut P: Expression of the
extracellular matrix metalloproteinase inducer (EMMPRIN) and the
matrix metalloproteinase-2 in bronchopulmonary and breast lesions.
J Histochem Cytochem. 47:1575–1580. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suzuki S, Sato M, Senoo H and Ishikawa K:
Direct cell-cell interaction enhances pro-MMP-2 production and
activation in co-culture of laryngeal cancer cells and fibroblast:
Involvement of EMMPRIN and MT1-MMP. Exp Cell Res. 293:259–266.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu T, Zhou M, Peng L, Kong S, Miao R, Shi
Y, Sheng H and Li L: Upregulation of CD147 promotes cell invasion,
epithelial-to-mesenchymal transition and activates MAPK/ERK
signaling pathway in c. Int J Clin Exp Pathol. 7:7432–7441.
2014.PubMed/NCBI
|
|
10
|
Hibino T, Sakaguchi M, Miyamoto S,
Yamamoto M, Motoyama A, Hosoi J, Shimokata T, Ito T, Tsuboi R and
Huh NH: S100A9 is a novel ligand of EMMPRIN that promotes melanoma
metastasis. Cancer Res. 73:172–183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takahashi M, Suzuki S and Ishikawa K:
Cyclophilin A-EMMPRIN interaction induces invasion of head and neck
squamous cell carcinoma. Oncol Rep. 27:198–203. 2012.PubMed/NCBI
|
|
12
|
Suzuki S, Honda K, Nanjo H, Iikawa N,
Tsuji T, Kawasaki Y, Yamazaki K, Sato T, Saito H, Shiina K and
Ishikawa K: CD147 expression correlates with lymph node metastasis
in T1-T2 squamous cell carcinoma of the tongue. Oncol Lett.
14:4670–4676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ru NY, Wu J, Chen ZN and Bian H:
HAb18G/CD147 is involved in TGF-β-induced epithelial-mesenchymal
transition and hepatocellular carcinoma invasion. Cell Biol Int.
39:44–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu F, Gu LN, Shan BE, Geng CZ and Sang
MX: Biomarkers for EMT and MET in breast cancer: An update. Oncol
Lett. 12:4869–4876. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Katsuno Y, Lamouille S and Derynck R:
TGF-β signaling and epithelial-mesenchymal transition in cancer
progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu C, Pan Y, He B, Wang B, Xu Y, Qu L,
Bao Q, Tian F and Wang S: Inhibition of CD147 gene expression via
RNA interference reduces tumor cell invasion, tumorigenicity and
increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2
cells. Oncol Rep. 25:425–432. 2011.PubMed/NCBI
|
|
17
|
Ma C, Wang J, Fan L and Guo Y: Inhibition
of CD147 expression promotes chemosensitivity in HNSCC cells by
deactivating MAPK/ERK signaling pathway. Exp Mol Pathol. 102:59–64.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suzuki S and Ishikawa K: Combined
inhibition of EMMPRIN and epidermal growth factor receptor prevents
the growth and migration of head and neck squamous cell carcinoma
cells. Int J Oncol. 44:912–917. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE,
Even C, et al: Nivolumab vs. investigator's choice in recurrent or
metastatic squamous cell carcinoma of the head and neck: 2-year
long-term survival update of CheckMate 141 with analyses by tumor
PD-L1 expression. Oral Oncol. 81:45–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kelderman S, Schumacher TN and Haanen JB:
Acquired and intrinsic resistance in cancer immunotherapy. Mol
Oncol. 8:1132–1139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bu X, Mahoney KM and Freeman GJ: Learning
from PD-1 resistance: New combination strategies. Trends Mol Med.
22:448–451. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Terry S, Savagner P, Ortiz-Cuaran S,
Mahjoubi L, Saintigny P, Thiery JP and Chouaib S: New insights into
the role of EMT in tumor immune escape. Mol Oncol. 11:824–846.
2017. View Article : Google Scholar : PubMed/NCBI
|
